SSS Sunvest Minerals Corp

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED STATES 

Stem Cell Therapeutics Corp. ("SCT" or the "Corporation") (TSX VENTURE:SSS) is
pleased to announce that it has entered into an agreement with J.F. Mackie &
Company Ltd. (the "Agent") under which they have agreed to act as the agent, on
a best-efforts basis, in connection with the sale of 8,340,000 units of the
Corporation ("Units") at a price of $0.12 per Unit (the "Offering") to raise
approximately $1.0 million. Each Unit will consist of one common share of the
Corporation ("Common Share") and one common share purchase warrant (the
"Warrants"). Each Warrant shall entitle the holder thereof to purchase one
Common Share at a price of $0.15 at any time during the period of 12 months from
the closing date. Additionally, SCT has granted the Agent an option to increase
the Offering by up to $500,000 on the same terms. Concurrently, the Corporation
will sell up to $1.0 million of additional Units on a non-brokered private
placement basis on the same terms as the Offering.


The maximum gross proceeds raised should the Agent's option be fully exercised,
including the concurrent non-brokered financing, will be $2.5 million. This
offering is subject to approval of the TSX-Venture Exchange. The Units will be
sold to accredited investors pursuant to applicable private placement exemptions
and all securities issued pursuant to this offering will be subject to a four
month hold period. The Offering is expected to close on or about October 29,
2009. SCT intends to use net proceeds of the Offering to support clinical
development programs and for general working capital purposes.


Dr. Alan Moore, President and CEO of SCT, commented as follows: 

"This financing will provide us with additional working capital to lengthen our
runway after completion of the NTx(TM)-265 stroke trial to facilitate potential
partnering discussions. It will also allow us to support the initiation of a
Phase II multiple sclerosis trial. We are pleased with the recruiting rate of
the stroke trial to date, which currently stands at 17 enrolled patients. We
have 10 sites recruiting patients at this time and expect to have additional
sites recruiting by the end of the month. We are gratified with the support
shown by our investors and the progress we have made at this early stage of the
stroke trial."


This press release shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of the securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. Forward-looking statements in this news release
include, but are not limited to, statements with respect to: the purposes for
which the Company intends to use the net proceeds of the Offering and the
expectations of the Company concerning the timing of obtaining additional
patient recruiting sites for the NTx(TM)-265 stroke trial. These forward-looking
statements involve risk and uncertainties, which may include, but are not
limited to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties related
to the regulatory approval process and other risks detailed from time to time in
the Company's ongoing quarterly and annual reporting.

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024